See more : Gabather AB (publ) (GABA.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Fulgent Genetics, Inc. (FLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fulgent Genetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Genex Power Limited (GNX.AX) Income Statement Analysis – Financial Results
- AVEVA Group plc (AVV.L) Income Statement Analysis – Financial Results
- Syrma SGS Technology Limited (SYRMA.NS) Income Statement Analysis – Financial Results
- Sogou Inc. (SOGO) Income Statement Analysis – Financial Results
- Novabase S.G.P.S., S.A. (NBA.LS) Income Statement Analysis – Financial Results
Fulgent Genetics, Inc. (FLGT)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.fulgentgenetics.com
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M | 18.73M | 18.28M | 9.58M | 1.28M | 0.00 |
Cost of Revenue | 184.76M | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M | 8.55M | 6.72M | 5.07M | 936.00K | 0.00 |
Gross Profit | 104.46M | 366.90M | 777.05M | 331.91M | 18.42M | 10.67M | 10.18M | 11.56M | 4.51M | 342.00K | 0.00 |
Gross Profit Ratio | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.94% | 54.35% | 63.22% | 47.07% | 26.76% | 0.00% |
Research & Development | 41.44M | 28.91M | 24.22M | 11.58M | 6.54M | 5.53M | 4.22M | 3.56M | 4.43M | 521.00K | 0.00 |
General & Administrative | 89.00M | 111.07M | 50.73M | 15.22M | 6.41M | 5.54M | 5.13M | 4.61M | 2.42M | 230.00K | 0.00 |
Selling & Marketing | 41.47M | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M | 4.22M | 2.47M | 2.67M | 581.00K | 0.00 |
SG&A | 130.47M | 149.99M | 75.17M | 30.17M | 12.31M | 10.19M | 9.36M | 7.08M | 5.09M | 811.00K | 0.00 |
Other Expenses | 0.00 | 6.50M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.34M |
Operating Expenses | 171.91M | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M | 13.58M | 10.64M | 9.52M | 1.33M | 104.34M |
Cost & Expenses | 364.51M | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M | 22.13M | 17.36M | 14.59M | 2.27M | 104.34M |
Interest Income | 21.44M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | 1.00K | 27.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.39M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 26.14M | 36.91M | 12.16M | 3.37M | 2.52M | 2.16M | 1.73M | 1.17M | 575.00K | 196.00K | 0.00 |
EBITDA | -46.55M | 221.59M | 675.95M | 290.16M | 1.68M | -2.91M | -1.75M | 2.09M | -4.44M | -794.00K | 104.34M |
EBITDA Ratio | -16.10% | 30.85% | 68.27% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -46.33% | -62.13% | 0.00% |
Operating Income | -72.70M | 178.53M | 675.95M | 290.16M | -428.00K | -5.06M | -3.40M | 919.00K | -5.01M | -990.00K | 104.34M |
Operating Income Ratio | -25.14% | 28.84% | 68.10% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -52.34% | -77.46% | 0.00% |
Total Other Income/Expenses | -101.39M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | -5.39M | 27.00K | 0.00 | 0.00 |
Income Before Tax | -174.09M | 184.03M | 677.30M | 291.68M | 409.00K | -4.62M | -2.92M | -4.47M | -4.99M | -990.00K | 104.34M |
Income Before Tax Ratio | -60.19% | 29.73% | 68.24% | 69.17% | 1.26% | -21.65% | -15.58% | -24.45% | -52.06% | -77.46% | 0.00% |
Income Tax Expense | 1.15M | 42.10M | 174.80M | 72.53M | 43.00K | -1.07M | -768.00K | 920.00K | 3.33M | 3.29M | 0.00 |
Net Income | -167.83M | 143.40M | 507.36M | 214.31M | 366.00K | -4.49M | -2.66M | -5.39M | -8.31M | -4.28M | 104.34M |
Net Income Ratio | -58.03% | 23.17% | 51.12% | 50.82% | 1.13% | -21.02% | -14.21% | -29.48% | -86.82% | -335.13% | 0.00% |
EPS | -5.63 | 4.76 | 17.13 | 9.64 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.48 |
EPS Diluted | -5.63 | 4.63 | 16.26 | 9.09 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.34 |
Weighted Avg Shares Out | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 29.96M |
Weighted Avg Shares Out (Dil) | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 31.20M |
Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q1 2022 Results - Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates
This Stock Grew 135% Last Year and Is Down 50% From Its Highs
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
This News Just Put Fulgent at the Top of My Buy List
Why Fulgent Genetics Shares Are Trading Higher Today
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
Fulgent Genetics: Now The Going Could Get Much Tougher
Fulgent Genetics: COVID Bolstered The Underlying Business
Is Fulgent Genetics (FLGT) a Suitable Value Investor Stock?
Source: https://incomestatements.info
Category: Stock Reports